YZYu-Xin Zhang

Yu-Xin Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu-Xin Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Neuroprotective effects of the pannexin-1 channel inhibitor: probenecid on spinal cord injury in rats

    by Qi Qi, Xiao-Xuan Wang, Jing-Lu Li, Yu-Qing Chen, Jian-Rong Chang, Jin Xi, He-Zuo Lü, Yu-Xin Zhang

    INTRODUCTION Spinal cord injury (SCI) is damage to the spinal cord caused by a sports accident, traffic accident, or fall from a height, which results in the loss of motor or sensory function, leading to a decrease in the quality of life and a heavy medical burden on the family and society (Gaojian et al., 2020). The treatment of SCI has been a challenge for the medical community because of the poor regenerative capacity of neurons after SCI and the rapid appearance of glial scarring, which makes it difficult to repair and reconstruct the spinal cord tissue and function (Wang et al., 2019). Therefore, it is significant to explore effective treatments for SCI to improve patients' quality of life and reduce the medical burden for families and society. Spinal cord injury contains two phases, the primary phase and the secondary phase (the main phase). The mechanisms of secondary injury after SCI are complex and include neuroinflammatory response, ischemia and hypoxia, lipid peroxidation, apoptosis, etc. (Wu and Xu, 2016). Qi et al. Neuroprotective Effects on SCI Among them, the neuroinflammatory response has been regarded as an important factor in the pathological process leading to secondary injury (Scholtes et al., 2012). The pathophysiological processes of secondary injury, such as apoptosis, edema, glial scarring, and inflammation in the injured tissue, severely impact the conduction function of nerves in the corresponding spinal cord segments. The inflammatory response during SCI includes local immune cell activation of the injury, the infiltration of peripheral immune cells, and the production of proinflammatory factors, which ultimately lead to spinal cord dysfunction (Sun et al., 2016). Effective and early use of anti-inflammatory drugs is of considerable importance to improve the local immune microenvironment and promote neuronal regeneration and recovery of spinal cord function. Probenecid, a sulfonamide derivative approved for use in 1951, has been used to treat gout and its adverse effects, and pharmacokinetics have been intensively studied (Baranova et al., 2004; Papadopoulos and Verkman, 2008). One study found that oxidative stress in nerve cells can be effectively inhibited by probenecid (Cheng and Kim, 2020). Another study showed that probenecid also acts as a pannexin-1 channel inhibitor and may inhibit the activation of inflammasomes (Silverman et al., 2009). Inflammasomes are multiprotein complexes that mainly consist of intracellular pattern recognition receptors (PRRs), apoptosis-associated speck-like protein containing a card (ASC), and pro-caspase-1 (Christgen et al., 2020). The pannexin-1 channel presents mainly in the brain, spinal cord, and thyroid gland (Bruzzone et al., 2003). It has a great effect on the activation of inflammasomes. In a study of a rat brain model of cognitive impairment, probenecid was found to inhibit the activation of nucleotide-binding oligomerization domain receptor pyrindomain-containing 1 (NLRP1) inflammasomes and reduce the activation of caspase-1, which in turn reduced the degree of cognitive impairment in rats (Mawhinney et al., 2011). Several studies have reported that probenecid can also reduce neuropathic pain in the spinal cord (Pineda-Farias et al., 2013; Bravo et al., 2014). These reports suggest that during the injury process of the central nervous system (CNS), probenecid has a neuroprotective and restorative effect on CNS injury, SCI has a similar process; however, it has not been reported whether this drug is useful for the treatment of SCI. In the immune microenvironment at the site of SCI, there are generally M1 and M2 two phenotypes of macrophages. They appear in all stages from SCI to recovery, especially playing an indispensable part in the secondary inflammatory response of SCI (Martinez et al., 2008; Milich et al., 2019; Zhang et al., 2020). M1 cells can produce high levels of proinflammatory cytokines, such as secreting proinflammatory factors, like tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β), which induce the production of inflammatory cascade responses. M2 cells can secrete anti-inflammatory factors like IL-4, IL-10, and other factors, which reduce the inflammatory response and promote wound healing (Gensel and Zhang, 2015). Whether probenecid affects the polarization of microglia/macrophages to exert neuroprotective effects on SCI is an important research value to explore new mechanisms of SCI pathology and find new targets for treatment. MATERIALS AND METHODS Experimental Animals In this experiment, a total of 98 SPF-grade women standard deviation (SD) rats (weight, 200–220 g; age, 8 weeks old) were used. All these rats were provided by Jinan Pengyue Experimental Animal Breeding Co., Ltd., Jinan, China, under license No. SCXK (Lu) 2019-0003. All surgical operations and postoperative care of SD rats during the experiment were approved by the Committee on the Laboratory Animal Care and Use of Bengbu Medical College. Experimental Methods Preparation of Spinal Cord Injury Models in Adult Rats Before performing the test, SD rats were housed in an environment with the appropriate humidity and temperature and given adequate feed and water for 5–7 days. Before surgery, the required surgical instruments were soaked in 75% alcohol (Shangdong Lierkang Co., Dezhou, China) for 30 min and sterilized with UV light for 30 min. During the operation, firstly, SD rats were anesthetized with 10% trichloroacetaldehyde intraperitoneally, then the rat hair around the T9 vertebral plate on the back of the rats was removed, the skin, fascia, and muscles of the corresponding part of T9 were cut open with a scalpel (Shanghai Medical Equipment Co., Shanghai, China), the T9 spinous process was removed with a bite forceps, and the vertebral plate was bitten along the interspinal foramen between T9 and T10 to fully expose the spinal cord, forming a circular opening of about 2.5 mm in diameter....

  • Semi-synthesis and in vitro anti-cancer effects evaluation of novel xanthohumol derivatives

    by Xiaolong Sun, Jie Chen, Di Huang, Feng Ding, Long Zhao, Hong-Mei Li, Xiang-Shu Wang, Yu-Xin Zhang, Cheng-Zhu Wu

    Xanthohumol (Xn) is a chalcone compound isolated from Humulus lupulus Linn., that has various biological activities. In this study, eight Xn derivatives were synthesized by Williamson, Mannich, Reimer-Tiemann, and Schiff base reactions, and evaluated for their in vitro cytotoxic activity against five human cancer cell lines (MDA-MB-231, MCF-7, CNE-2Z, SMMC-7721, and H1975). Among these compounds, 2-((E)-2,4-dihydroxy-5-((E)-3-(4-hydroxyphenyl)acryloyl)-6-methoxy-3-(3- methylbut-2-en-1-yl)benzylidene)hydrazine-1-carboximidamide (8) exhibited the most potent cytotoxic activity against the five cancer cells, with IC50 values ranging from 4.87 to 14.35 µM. Wound-healing and transwell assays showed that compound 8 inhibited the migration and invasion of MDA-MB-231 cells by down-regulation HIF-1α, MMP-2 and MMP-9 protein expression. We further demonstrated that compound 8 induced apoptosis of MDA-MB-231 cells by increasing of Bax/Bcl-2 ratio and down-regulation of Akt protein expression.


  • Open Access

    Isobavachalcone Induces Multiple Cell Death in Human Triple-Negative Breast Cancer MDA-MB-231 Cells

    by Cheng-Zhu Wu, Mei-Jia Gao, Jie Chen, Xiao-Long Sun, Ke-Yi Zhang, Yi-Qun Dai, Tao Ma, Hong-Mei Li, Yu-Xin Zhang

    Standardized treatment guidelines and effective drugs are not available for human triple-negative breast cancer (TNBC). Many efforts have recently been exerted to investigate the efficacy of natural compounds as anticancer agents owing to their low toxicity. However, no study has examined the effects of isobavachalcone (IBC) on the programmed cell death (PCD) of human triple-negative breast MDA-MB-231 cancer cells. In this study, IBC substantially inhibited the proliferation of MDA-MB-231 cells in concentration- and time-dependent manners. In addition, we found that IBC induced multiple cell death processes, such as apoptosis, necroptosis, and autophagy in MDA-MB-231 cells. The initial mechanism of IBC-mediated cell death in MDA-MB-231 cells involves the downregulation of Akt and p-Akt-473, an increase in the Bax/Bcl-2 ratio, and cleaved caspases-3 induced apoptosis; the upregulation of RIP3, p-RIP3 and MLKL induced necroptosis; as well as a simultaneous increase in LC3-II/I ratio induced autophagy. In addition, we observed that IBC induced mitochondrial dysfunction, thereby decreasing cellular ATP levels and increasing reactive oxygen species accumulation to induce PCD. These results suggest that IBC is a promising lead compound with anti-TNBC activity.


  • Open Access

    Neuroprotective Effects of the Pannexin-1 Channel Inhibitor: Probenecid on Spinal Cord Injury in Rats

    by Qi Qi, Xiao-Xuan Wang, Jing-Lu Li, Yu-Qing Chen, Jian-Rong Chang, Jin Xi, He-Zuo Lü, Yu-Xin Zhang

    Proinflammatory immune cell subsets constitute the majority in the local microenvironment after spinal cord injury (SCI), leading to secondary pathological injury. Previous studies have demonstrated that inflammasomes act as an important part of the inflammatory process after SCI. Probenecid, an inhibitor of the Pannexin-1 channel, can inhibit the activation of inflammasomes. This article focuses on the effects of probenecid on the local immune microenvironment, histopathology, and behavior of SCI. Our data show that probenecid inhibited the expression and activation of nucleotide-binding oligomerization domain receptor pyrindomain-containing 1 (NLRP1), apoptosis-associated speck-like protein containing a CARD (ASC) and caspase-1, interleukin-1β (IL-1β), and caspase-3 proteins associated with inflammasomes, thereby suppressing the proportion of M1 cells. And consequently, probenecid reduced the lesion area and demyelination in SCI. Moreover, the drug increased the survival of motor neurons, which resulted in tissue repair and improved locomotor function in the injured SC. Altogether, existing studies indicated that probenecid can alleviate inflammation by blocking Pannexin-1 channels to inhibit the expression of caspase-1 and IL-1β, which in turn restores the balance of immune cell subsets and exerts neuroprotective effects in rats with SCI.


  • [Isobavachalcone induces cell death through multiple pathways in human breast cancer MCF-7 cells].

    by 心张 玉, 佳高 美, 林朱 美, 梅李 红, 马 涛, 柱吴 成

    To explore the effects of isobavachalcone (IBC) on cell death of human breast cancer MCF-7 cells and explore the possible mechanism. MCF-7 cells were treated with different concentrations of IBC, and the changes in cell proliferation were assessed using MTT assay. Apoptosis of MCF-7 cells following treatment with 10, 20, and 40 μmol/L IBC was analyzed using flow cytometry with annexin V-FITC/PI double staining and fluorescence microscopy, and the expressions of apoptosis- and autophagy-related proteins (Bax, Bcl-2, Akt, p-Akt, p62, and LC3) were detected with Western blotting. Electron microscopy was used to observe the changes in submicrostructure of the cells following treatment with 40 μmol/L IBC. JC-1 assay kit, ATP assay kit, and reactive oxygen species (ROS) kit were used to determine the effect of IBC on mitochondrial function of the cells. MTT assay showed that IBC significantly inhibited the proliferation of MCF-7 cells in a concentration- and time-dependent manner, with IC50 values of 38.46, 31.31, and 28.26 μmol/L at 24, 48, and 72 h, respectively. IBC also concentration-dependently induced apoptosis of MCF-7 cells. IBC-induced cell death was inhibited by z-VAD-fmk, a caspase inhibitor (P < 0.05), but not by the necroptosis inhibitor necrostatin-1 (Nec-1). Western blotting showed that IBC-induced MCF-7 cell apoptosis by increasing Bax expression and down-regulating the expressions of Bcl-2, Akt and p-Akt-473 (all P < 0.05). With the increase of IBC concentration, the expression of autophagy-related protein p62 and the LC3-II/I ratio increased progressively. Electron microscopy revealed the presence of autophagic bodies in IBC-treated MCF-7 cells. IBC treatment also resulted in decreased mitochondrial membrane potential and intracellular ATP level and increased ROS accumulation in MCF-7 cells (P < 0.05). IBC is capable of inducing both apoptosis and autophagy in MCF-7 cells, suggesting the potential value of IBC as a lead compound in the development of anti-breast cancer agents.